An experimental vaccine that attacks the malaria parasite in its early stages prevents a significant number of malaria cases, and should move closer to licensing and widespread use, according to a new ...

Natural malaria infections have been genetically analysed at a higher resolution than ever before, giving insights that could help understand and block transmission. For the first time, the ...

Global malaria cases are increasing despite vaccine progress, with funding gaps and resistance limiting the prevention and ...

A new malaria vaccine achieves an unparalleled 89% efficacy by targeting late-liver-stage antigens, unlocking new horizons in the fight against global disease. Study: Safety and Efficacy of ...

I’ve been covering HIV for nearly 15 years and through almost all that time – as the pandemic devastated large swathes of the developing world -- the cry has repeatedly gone up: “When will we have a ...

Researchers studying the malaria parasite Plasmodium falciparum have discovered a previously unknown stage in its life cycle that appears to be crucial for reproduction. This is important because ...

The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those who have already received pre-erythrocytic ...

Researchers have identified a compound, ML-901, that showed highly specific and potent inhibition of the malaria parasite. ML-901 exerted activity against all stages of the malaria parasite lifecycle ...

Almost all the drugs that are widely used today against Plasmodium spp., the causative agent of malaria, target the asexual blood stages of the parasite. Widespread drug resistance severely restricts ...

Malaria symptoms occur once the parasite's asexual stages begin replicating inside red blood cells. However, these asexual forms must transform into male and female stages called gametocytes in order ...

TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million 1) in five R&D projects ...